AnaptysBio, Inc.
NASDAQ:ANAB
36.57 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 17.157 | 10.287 | 63.175 | 75 | 8 | 5 | 10 | 16.684 | 17.571 | 15.838 | 5.483 |
| Cost of Revenue
| 2.376 | 2.335 | 98.496 | 80.025 | 99.338 | 56.196 | 29.443 | 15.419 | 17.304 | 8.614 | 8.82 |
| Gross Profit
| 14.781 | 7.952 | -35.321 | -5.025 | -91.338 | -51.196 | -19.443 | 1.265 | 0.267 | 7.224 | -3.337 |
| Gross Profit Ratio
| 0.862 | 0.773 | -0.559 | -0.067 | -11.417 | -10.239 | -1.944 | 0.076 | 0.015 | 0.456 | -0.609 |
| Reseach & Development Expenses
| 132.283 | 88.798 | 98.496 | 80.025 | 99.338 | 56.196 | 29.443 | 15.419 | 17.304 | 8.614 | 8.82 |
| General & Administrative Expenses
| 41.946 | 36.643 | 21.493 | 18.854 | 16.094 | 15.526 | 9.338 | 4.29 | 3.589 | 2.354 | 1.95 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 41.946 | 36.643 | 21.493 | 18.854 | 16.094 | 15.526 | 9.338 | 4.29 | 3.589 | 2.354 | 1.95 |
| Other Expenses
| -0.002 | 0.012 | 0.037 | -0.011 | 0.001 | -0.159 | 0.229 | -0.02 | -0.207 | 0.002 | 0.001 |
| Operating Expenses
| 174.229 | 125.441 | 119.989 | 98.879 | 115.432 | 71.722 | 38.781 | 19.709 | 20.893 | 10.968 | 10.77 |
| Operating Income
| -164.411 | -115.154 | -56.814 | -23.879 | -107.432 | -66.722 | -28.781 | -3.025 | -3.322 | 4.87 | -5.287 |
| Operating Income Ratio
| -9.583 | -11.194 | -0.899 | -0.318 | -13.429 | -13.344 | -2.878 | -0.181 | -0.189 | 0.307 | -0.964 |
| Total Other Income Expenses Net
| -7.341 | -13.546 | -0.982 | 3.948 | 9.944 | -0.159 | -1.137 | -0.776 | -1.484 | -0.057 | 0.628 |
| Income Before Tax
| -163.623 | -128.7 | -57.796 | -19.931 | -97.488 | -61.848 | -30.07 | -4.259 | -5.266 | 3.532 | -5.545 |
| Income Before Tax Ratio
| -9.537 | -12.511 | -0.915 | -0.266 | -12.186 | -12.37 | -3.007 | -0.255 | -0.3 | 0.223 | -1.011 |
| Income Tax Expense
| -0.004 | 0.024 | -0.603 | -0.011 | -0.152 | -0.192 | 1.821 | 0.205 | 0.139 | 1.283 | 0.887 |
| Net Income
| -163.619 | -128.724 | -57.193 | -19.92 | -97.336 | -61.656 | -30.07 | -4.259 | -5.405 | 3.532 | -5.545 |
| Net Income Ratio
| -9.537 | -12.513 | -0.905 | -0.266 | -12.167 | -12.331 | -3.007 | -0.255 | -0.308 | 0.223 | -1.011 |
| EPS
| -6.08 | -4.57 | -2.08 | -0.73 | -3.6 | -2.5 | -1.52 | -0.23 | -0.38 | 0.016 | -0.095 |
| EPS Diluted
| -6.08 | -4.57 | -2.08 | -0.73 | -3.6 | -2.5 | -1.52 | -0.23 | -0.36 | 0.016 | -0.093 |
| EBITDA
| -135.825 | -107.592 | -56.346 | -19.372 | -96.447 | -60.196 | -26.929 | -3.045 | -3.255 | 5.18 | -4.706 |
| EBITDA Ratio
| -7.917 | -10.459 | -0.892 | -0.258 | -12.056 | -12.039 | -2.693 | -0.183 | -0.185 | 0.327 | -0.858 |